Clinical Trial Detail

NCT ID NCT03476174
Title Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Ralph Hauke
Indications

melanoma

Therapies

Aldesleukin + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.